Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rahul Khurana
Pennsylvania State Univ Hershey Med Ctr, Department: Ophthalmology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Genentech
Payment for services (e.g., consulting fees, honoraria, paid authorship)
This project evaluates anti-VEGF treatment. In the initial phase of the study, one of the study drugs (bevacizumab) that is FDA approved and sold by Genentech was supplied by Leiter’s compounding pharmacy and used off-label in this study. Regeneron also provided drug for the initial SCORE2 study.
The SCORE2 Long-Term Follow-Up (SCORE2 LTF)
Project Narrative It is anticipated that anti-VEGF therapy will remain a standard of care treatment for eyes with macular edema due to CRVO or HRVO for years to come. The SCORE2 LTF is a unique opportunity to leverage the information collected from the large and well-characterized SCORE2 patient cohort. Because of the large number of patients with CRVO or HRVO enrolled in SCORE2 (n=362) and the detailed information gathered, the SCORE2 LTF will provide by far the most comprehensive information available on the longer-term (3-5 years) effects of anti- VEGF therapy for patients with macular edema due to CRVO or HRVO; provide prognostic information to patients and their ophthalmologists with respect to visual acuity, number of anti- VEGF injections, duration of anti-VEGF therapy, and safety profile; and establish a baseline for comparison of future treatments of CRVO and HRVO. �
Filed on June 25, 2019.
Tell us what you know about Rahul Khurana's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Rahul Khurana”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Rahul Khurana | Pennsylvania State Univ Hershey Med Ctr | Conflict of Interest | Allergan, Inc. | $5,000 - $9,999 |
| Rahul Khurana | Pennsylvania State Univ Hershey Med Ctr | Conflict of Interest | Regeneron Pharmaceuticals | $10,000 - $19,999 |
| Rahul Khurana | Pennsylvania State Univ Hershey Med Ctr | Conflict of Interest | Genentech | $20,000 - $39,999 |
| Rahul Khurana | Pennsylvania State Univ Hershey Med Ctr | Conflict of Interest | Regeneron Pharmaceuticals | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.